Skip to main content

Table 5 Serious adverse events

From: Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Motive for seriousness

Events

N

%*

Caused death

Acute myocardial infarct

5

 

Sudden cardiac death

2

 

Acute pulmonary edema

2

 

Ventricular fibrillation

1

 

Uncompensated heart insufficiency

1

 

Ischemic stroke

1

 

Acute respiratory failure

1

 

Acute gastroenterocolitis

1

 

Diabetic ketoacidosis-septic shock

1

 
 

Subtotal

15

0.8%

Endangered life

Acute pulmonary edema

2

 

Loss of consciousness

2

 

Local infection

1

 

Glottic spasm

1

 

Faintness

1

 
 

Subtotal

7

0.4%

Prolonged hospitalization

Local infection

4

0.2%

Produced disability

Local infection

5

0.3%

TOTAL

31

1.7%

  1. *Percent calculated from 1851 treatment cycles.